Robert J. Temple

3.5k citations

27 papers · 1.2k indexed · 2 hit papers · h-index 15

Impact in

Statistics and Probability top 2%
- Statistical Methods in Clinical Trials
Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism

Papers in ⓘ

Statistics and Probability 6
- Statistical Methods in Clinical Trials 6
Pharmacology 6
- Pharmacogenetics and Drug Metabolism 4
- Pharmaceutical industry and healthcare 2

Co-authors: Zeshan Qureshi (1 shared paper)Trisha Greenhalgh (1 shared paper)Jessica P. J. Larwood (1 shared paper)Nicholas Jones (1 shared paper)Lydia Bourouiba (1 shared paper)Janet Woodcock (2 shared papers)Ellis F. Unger (3 shared papers)Pamela E. Scott (1 shared paper)
Journals: The Journal of Clinical Psychiatry (4 papers)Clinical Pharmacology & Therapeutics (2 papers)Drug Information Journal (2 papers)Pharmaceutical Research (2 papers)New England Journal of Medicine (2 papers)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Robert J. Temple

27 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

Two metres or one: what is the evidence for physical distancing in covid-19? 2020 · 267 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 BMJ
2018 Journal of the American College of Cardiology

Peers

Countries citing papers authored by Robert J. Temple

Since Specialization

Citations

This map shows the geographic impact of Robert J. Temple's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Temple with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Temple more than expected).

Fields of papers citing papers by Robert J. Temple

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Temple. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Temple. The network helps show where Robert J. Temple may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert J. Temple, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert J. Temple Line = papers co-authored together Robert J. Temple links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Two metres or one: what is the evidence for physical distancing in covid-19? BMJ ·Nicholas Jones, Zeshan Qureshi, Robert J. Temple, Jessica P. J. Larwood, Trisha Greenhalgh, Lydia Bourouiba Hit paper breakdown →	2020	267
2	Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs Journal of the American College of Cardiology ·Pamela E. Scott, Ellis F. Unger, Marjorie Jenkins, Mary Southworth, Tzu‐Yun McDowell, Ruth J. Geller, Merina Elahi, Robert J. Temple, Janet Woodcock Hit paper breakdown →	2018	233
3	Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development Clinical Pharmacology & Therapeutics ·Carl C. Peck, William H. Barr, Leslie Z. Benet, Jerry M. Collins, Robert E. Desjardins, Daniel E. Furst, John G. Harter, Gerhard Levy, Thomas M. Ludden, John H. Rodman, Lilly Sanathana, Jerome J. Schentag, Vinod P. Shah, Lewis B. Sheiner, Jerome P. Skelly, Donald R. Stanski, Robert J. Temple, C.T. Viswanathan, Judi Weissinger, Avraham Yacobi	1992	141
4	Therapeutic-Class Wars -- Drug Promotion in a Competitive Marketplace New England Journal of Medicine ·David A. Kessler, Janet L. Rose, Robert J. Temple, Renie Schapiro, Joseph P. Griffin	1994	92
5	The Imperative of Overcoming Barriers to the Conduct of Large, Simple Trials JAMA ·Zubin J. Eapen, Michael S. Lauer, Robert J. Temple	2014	62
6	Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development Journal of Pharmaceutical Sciences ·Carl C. Peck, William H. Barr, Leslie Z. Benet, Jerry M. Collins, Robert E. Desjardins, Daniel E. Furst, John G. Harter, Gerhard Levy, Thomas M. Ludden, John H. Rodman, Lilly Sanathanan, Jerome J. Schentag, Vinod P. Shah, Lewis B. Sheiner, Jerome P. Skelly, Donald R. Stanski, Robert J. Temple, C.T. Viswanathan, Judi Weissinger, Avraham Yacobi	1992	49
7	Special study designs: early escape, enrichment, studies in non-responders Communication in Statistics- Theory and Methods ·Robert J. Temple	1994	49
8	Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development Pharmaceutical Research ·Carl C. Peck, William H. Barr, Leslie Z. Benet, Jerry M. Collins, Robert E. Desjardins, Daniel E. Furst, John G. Harter, Gerhard Levy, Thomas M. Ludden, John H. Rodman, Lilly Sanathanan, Jerome J. Schentag, Vinod P. Shah, Lewis B. Sheiner, Jerome P. Skelly, Donald R. Stanski, Robert J. Temple, C.T. Viswanathan, Judi Weissinger, Avraham Yacobi	1992	41
9	New FDA Regulation to Improve Safety Reporting in Clinical Trials New England Journal of Medicine ·Rachel Behrman Sherman, Janet Woodcock, Janet M. Norden, Cheryl Grandinetti, Robert J. Temple	2011	38
10	Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development The Journal of Clinical Pharmacology ·Carl C. Peck, William H. Barr, Leslie Z. Benet, Jerry M. Collins, Robert E. Desjardins, Daniel E. Furst, John G. Harter, Gerhard Levy, Thomas M. Ludden, John H. Rodman, Lilly Sanathanan, Jerome J. Schentag, Vinod P. Shah, Lewis B. Sheiner, Jerome P. Skelly, Donald R. Stanski, Robert J. Temple, C.T. Viswanathan, Judi Weissinger, Avraham Yacobi	1994	37
11	When are clinical trials of a given agent vs. placebo no longer appropriate or feasible? Controlled Clinical Trials ·Robert J. Temple	1997	36
12	Report of the Workshop on Controlled-Release Dosage Forms: Issues and Controversies Pharmaceutical Research ·Jerome P. Skelly, William H. Barr, Leslie Z. Benet, James T. Doluisio, Arthur H. Goldberg, Gerhard Levy, David Löwenthal, Joseph R. Robinson, Vinod P. Shah, Robert J. Temple, Avraham Yacobi	1987	35
13	The US Food and Drug Administration’s Perspective on the New Antipsychotic Pimavanserin The Journal of Clinical Psychiatry ·Mitchell Mathis, Brendan M Muoio, Paul Andreason, Amy M. Avila, Tiffany Farchione, Aisar Atrakchi, Robert J. Temple	2017	29
14	The US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine The Journal of Clinical Psychiatry ·Jing Zhang, Mitchell Mathis, Jenn W. Sellers, George Kordzakhia, André J. Jackson, Antonia Dow, Peiling Yang, Linda H. Fossom, Hao‐Jie Zhu, Hiren Patel, Ellis F. Unger, Robert J. Temple	2014	26
15	Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials The Journal of Clinical Psychiatry ·Ni A. Khin, Phillip D. Kronstein, Peiling Yang, Eiji Ishida, Hung Hung, Mitchell Mathis, Ellis F. Unger, Robert J. Temple	2015	14
16	Independent data monitoring committees: Preparing a path for the future American Heart Journal ·Connie N. Hess, Matthew T. Roe, C. Michael Gibson, Robert J. Temple, Michael Pencina, Deborah A. Zarin, Kevin J. Anstrom, John H. Alexander, Rachel E. Sherman, Fred T. Fiedorek, Kenneth W. Mahaffey, Kerry L. Lee, Shein‐Chung Chow, Paul W. Armstrong, Robert M. Califf	2014	13
17	Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021 JAMA Network Open ·Andrea N. Monge, Daniel W. Sigelman, Robert J. Temple, Harinder Singh Chahal	2022	13
18	Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials The Journal of Clinical Psychiatry ·Phillip D. Kronstein, Eiji Ishida, Ni A. Khin, Eric H. Chang, Hung Hung, Robert J. Temple, Peiling Yang	2015	10
19	The Effect of l-Valine on Enzyme Synthesis in Escherichia coli K-12 Journal of Biological Chemistry ·Robert J. Temple, H. E. Umbarger, Boris Magasanik	1965	9
20	Study Designs in Osteoporosis Journal of Bone and Mineral Research ·Robert J. Temple	2003	8

About Robert J. Temple

Robert J. Temple is a scholar working on Statistics and Probability, Pharmacology, Statistics, Probability and Uncertainty, Pediatrics, Perinatology and Child Health and Economics and Econometrics, having authored 27 papers that have together received 1.2k indexed citations. Recurring topics across this work include Pharmaceutical studies and practices (6 papers), Statistical Methods in Clinical Trials (6 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers), Pharmacogenetics and Drug Metabolism (4 papers), Pharmaceutical Economics and Policy (4 papers), Meta-analysis and systematic reviews (3 papers), Cancer Treatment and Pharmacology (2 papers) and Pharmaceutical industry and healthcare (2 papers). The work is most often cited by research in Statistics and Probability (173 citations), Pharmacology (152 citations), Modeling and Simulation (79 citations), Economics and Econometrics (290 citations) and Public Health, Environmental and Occupational Health (220 citations). Robert J. Temple has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Zeshan Qureshi, Trisha Greenhalgh, Jessica P. J. Larwood, Nicholas Jones, Lydia Bourouiba, Janet Woodcock, Ellis F. Unger, Pamela E. Scott, Tzu‐Yun McDowell and Marjorie Jenkins. Their work appears in journals such as The Journal of Clinical Psychiatry, Clinical Pharmacology & Therapeutics, Drug Information Journal, Pharmaceutical Research and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact